

# JOURNÉE NATIONALE DE LA BIOPRODUCTION DE BIOMÉDICAMENTS

 5 Juin 2025

En collaboration  
avec  
FRANCE  
**biolead**



## **Second edition of the National Biomanufacturing of Biomedicines Day in France #NBBDFrance2025: HTL Biotechnology mobilizes to promote a promising industry**

After a successful first edition in 2024, the National Biomanufacturing of Biomedicines Day (NBBD) returns on June 5<sup>th</sup>, 2025, with a reinforced ambition: to accelerate the attractiveness of the sector, both economically and in terms of job opportunities. This year, the event will focus on pursuing education around the bioproduction value chain and its essential role in public health, enhancing the sector's economic attractiveness and highlighting its innovation potential, and promoting career opportunities and available trainings to attract and retain talented professionals.

Through a series of initiatives implemented across France and digitally, the NBBD has become an essential event for all sector stakeholders: research institutes, training actors, pharmaceutical and biotechnology companies, CDMOs, CROs, equipment manufacturers, technology solution providers or consumables, competitiveness clusters, associations, and professional unions.

### **Together, let's reveal an essential link for the health of tomorrow**

A biomedicine or biological medicine is defined as any medicine whose active substance is produced entirely or partially from a biological source and whose characterization and quality determination require a combination of physical, chemical, and biological tests, as well as knowledge of its manufacturing process and control.

Alongside synthetic medicines, which are medicines whose active ingredient is produced by synthesis in a laboratory, biomedicines complement the therapeutic portfolio. They address unmet needs.

# JOURNÉE NATIONALE DE LA BIOPRODUCTION DE BIOMÉDICAMENTS

 5 Juin 2025

En collaboration  
avec  
FRANCE  
**biolead**



## **2025: Amplifying the visibility of the Biomanufacturing of Biomedicines in France**

The second National Biomanufacturing of Biomedicines Day returns on June 5<sup>th</sup> 2025, with reinforced ambition: to accelerate the attractiveness of the sector, both economically and in terms of career opportunities.

With capacities having increased by 60% in 6 years, accelerated private investments over the last 3 years, and the largest number of biomanufacturing sites in Europe, the French sector is becoming the European leader. Its structured ecosystem allows it to meet the scientific, technological, and industrial challenges of the market. Supported by the France 2030 plan, the sector benefits from a favorable environment for innovation and investment.

To support this strong growth, the biomanufacturing sector of biomedicines is recruiting for innovative, specialized, and meaningful jobs. Present throughout the territory, it combines local roots with international influence. Thanks to a varied training offer and coordinated initiatives, the sector aims to attract students, job seekers, and professionals in career transition.

NBBBD 2025 will mobilize all stakeholders to strengthen the attractiveness and influence of French biomanufacturing.

### **ABOUT HTL BIOTECHNOLOGY**

HTL Biotechnology is a French biotech and a world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides). These biopolymers are used by healthcare companies for the development of treatments in various cutting-edge therapeutic fields such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc (HTL BII - New Jersey), a recombinant protein

# JOURNÉE NATIONALE DE LA BIOPRODUCTION DE BIOMÉDICAMENTS

 5 Juin 2025

En collaboration  
avec  
FRANCE  
**biolead**



platform whose most advanced product is recombinant human collagen type III (rhCOL3) within a world-class scientific research center. To meet the world's growing demand for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company combines production, innovation, R&D and quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide.

To find out more about HTL: <https://htlbiotech.com/>

LinkedIn: [HTL Biotechnology](#)

## ABOUT FRANCE BIOLEAD

France BioLead is the representative of the French biomanufacturing sector of biomedicines, created under the aegis of the State, the Strategic Committee for Health Industries and Technologies, and 15 founding members.

France BioLead brings together the entire value chain of French biomanufacturing: academic research, education and training actors, industrials (Pharmaceutical and Biotechnology companies, CDMOs, CROs, equipment manufacturers, technology solution providers or consumables), competitiveness clusters, competence centers, associations, and professional unions.

Our mission? Structure, lead, facilitate, and promote the sector and its actors.

Our ambition? Make France the European leader in biomanufacturing and ensure better access to today's and tomorrow's therapeutic innovations for the greatest number. France BioLead has over 65 members as of March 2025.

Discover them here: [www.france-biolead.fr/content/nos-membres-et-adherents](http://www.france-biolead.fr/content/nos-membres-et-adherents)

### Press contacts:

Léa Morales \ 06 30 69 50 16 \ [lea.morales@tbwa-corporate.com](mailto:lea.morales@tbwa-corporate.com)

Pierre Yves Gallety \ 06 42 98 71 47 \ [pierre-yves.gallety@tbwa-corporate.com](mailto:pierre-yves.gallety@tbwa-corporate.com)